BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15467732)

  • 41. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.
    Sensi M; Nicolini G; Petti C; Bersani I; Lozupone F; Molla A; Vegetti C; Nonaka D; Mortarini R; Parmiani G; Fais S; Anichini A
    Oncogene; 2006 Jun; 25(24):3357-64. PubMed ID: 16462768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma.
    Bar EE; Lin A; Tihan T; Burger PC; Eberhart CG
    J Neuropathol Exp Neurol; 2008 Sep; 67(9):878-87. PubMed ID: 18716556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
    Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
    J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity.
    Fusi A; Berdel R; Havemann S; Nonnenmacher A; Keilholz U
    Eur J Cancer; 2011 Sep; 47(13):1971-6. PubMed ID: 21570823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
    Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
    Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.
    Huntington JT; Shields JM; Der CJ; Wyatt CA; Benbow U; Slingluff CL; Brinckerhoff CE
    J Biol Chem; 2004 Aug; 279(32):33168-76. PubMed ID: 15184373
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Analysis of BRAF mutation and extracellular regulated protein kinases activation in nasal mucosa melanomas].
    Li HY; Zhou L; Tian J; Cong N
    Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(48):3399-402. PubMed ID: 21223812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.
    Sumimoto H; Miyagishi M; Miyoshi H; Yamagata S; Shimizu A; Taira K; Kawakami Y
    Oncogene; 2004 Aug; 23(36):6031-9. PubMed ID: 15208655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma.
    Yang L; Chen Y; Cui T; Knösel T; Zhang Q; Geier C; Katenkamp D; Petersen I
    Hum Pathol; 2012 Sep; 43(9):1463-70. PubMed ID: 22406360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas.
    Ewing I; Pedder-Smith S; Franchi G; Ruscica M; Emery M; Vax V; Garcia E; Czirják S; Hanzély Z; Kola B; Korbonits M; Grossman AB
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):348-52. PubMed ID: 17302867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
    Uribe P; Andrade L; Gonzalez S
    J Invest Dermatol; 2006 Jan; 126(1):161-6. PubMed ID: 16417232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
    Whipple CA; Boni A; Fisher JL; Hampton TH; Tsongalis GJ; Mellinger DL; Yan S; Tafe LJ; Brinckerhoff CE; Turk MJ; Mullins DW; Fadul CE; Ernstoff MS
    Melanoma Res; 2016 Jun; 26(3):223-35. PubMed ID: 26974965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
    Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
    J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
    Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
    Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis.
    Zhao Y; Zhang Y; Yang Z; Li A; Dong J
    Biochem Biophys Res Commun; 2008 Jun; 370(3):509-13. PubMed ID: 18402768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
    Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
    Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
    [TBL] [Abstract][Full Text] [Related]  

  • 60. B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis.
    Boisvert-Adamo K; Aplin AE
    Oncogene; 2006 Aug; 25(35):4848-56. PubMed ID: 16547495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.